proposed that p-gp inhibitors with higher efficacious ability are to be used to show good results to overcome MDR. Such inhibitor is taken in the article as tariquidar. P-gp, however, can further be expressed within general tissues such as the barriers in the blood brain, track of gastrointestinal nature, spleen as well as kidney (Patel et al., 2011). For maximizing the P-gp inhibitor efficacy as well as reducing the toxicity systemically, it becomes essential to consider limiting the P-gp inhibitors exposure as well as the drugs of anti-cancer for normal tissues. This further results in increasing the tumor cells co-localization.

Within the article, the authors indulged in investigating the P-gp inhibitor co-delivery and drug of cytotoxic nature, namely paclitaxel within the cells of tumor for revering the MDR (multi-drug resistance) through the use of liposomes with long circulation (Patel et al., 2011). These liposomes along with tariquidar depicted essential resistant variant re-sensitization for the paclitaxel resistant variance. This could have a correlation with enhanced paclitaxel accumulation within the cells of tumor.